Inside The Epic Battle Between Danone And Lifeway Foods—And Its Squabbling Founding Family

The Epic Battle Between Danone and Lifeway Foods

Key Concepts:

• Hostile Takeover
• Poison Pill
• Shareholder Agreement
• Right of First Refusal
• Undervaluation
• Competitive Bidding Process
• Fiduciary Duty
• Trade Secrets
• Predatory Practices

Danone's Takeover Attempt

• Initial Contact: In September, Danone, holding just under 25% of Lifeway Foods, requested an urgent meeting with Lifeway CEO Julie Smolyansky to announce their intention to acquire a controlling stake.
• Smolyansky's Resistance: Smolyansky, controlling 45% of Lifeway's stock with her mother and brother, opposed the takeover, accusing Danone of "bullying" and "predatory" behavior.
• Accusations Against Danone: Lifeway accuses Danone of:
  • Blocking international expansion.
  • Refusing to help source cheaper ingredients.
  • Using their board seat to access competitive information and trade secrets, especially after acquiring Wallaby Yogurt in 2017.
• Danone's Defense: Danone denies the accusations, stating Lifeway shielded information from their board representative and that Lifeway wouldn't be where it is today without their initial investment. Danone emphasizes that Lifeway is a publicly owned company, not a family business.

The 1999 Agreement

• Smolyansky's Claim: Smolyansky argues that the 1999 agreement with Danone, where they invested $6.5 million (approximately $12 million today) for a 15% stake, was exploitative due to her father's lack of business education.
• Terms of the Agreement: The agreement and a "support agreement" signed in conjunction allegedly hamstring Lifeway.
• Share Restrictions: The family can only sell up to 2% of their shares annually; otherwise, Danone has the right of first refusal.

Buyout Offers and Rejection

• Initial Offer: Following the September call, Danone offered shareholders $25 per share, a 19% premium.
• Second Offer: This was rejected by Lifeway's board, chaired by Smolyansky. Danone then increased its bid to $390 million, or $27 per share.
• Continued Rejection: Lifeway's board rejected the second offer as well, deeming it an undervaluation of the company.
• Analyst Support: Lake Street Capital Markets analyst Ben Cleave agrees, stating that deals for natural foods typically command multiples of over three times sales, while Danone's offers are less than two times sales.

Poison Pill Defense

• Implementation: Prior to the second bid, Lifeway's board implemented a "poison pill" defense.
• Mechanism: This gives existing shareholders the right to buy additional shares if any shareholder exceeding 20% ownership (like Danone) increases their stake, diluting the takeover attempt.
• Family Share Protection: The poison pill also prevents Smolyansky's mother, Ludmila Miller, and her brother, Edward Smolyansky, from selling their shares to Danone.

Shareholder Ownership and Disputes

• Current Ownership:
  • Danone: Nearly 23%
  • Julie Smolyansky: Nearly 18%
  • Edward Smolyansky: Nearly 21%
  • Ludmila Miller: 6%
• Edward's Dispute: Edward disputes Julie's total share count, claiming over 300,000 shares are invalid.
• Family Stake Decline: The combined family stake has fallen below 50% due to share sales.

Lawsuits and Counter-Suits

• Danone's Lawsuit: Danone filed a lawsuit in Illinois state court alleging Lifeway violated the shareholder agreement by issuing approximately $7 million worth of shares to Smolyansky in December 2024.
• Lifeway's Counter-Suit: Lifeway filed a counter-suit a few weeks later.

Conclusion

The battle between Danone and Lifeway Foods is a complex struggle involving accusations of predatory behavior, shareholder rights, and family legacy. Danone's attempts to acquire a controlling stake in Lifeway have been met with strong resistance from the Smolyansky family, who believe the offers undervalue the company and threaten its future. The implementation of a poison pill defense and ongoing lawsuits highlight the intensity of the conflict and the high stakes involved. The core issue revolves around differing perspectives on the company's value and the validity of the 1999 shareholder agreement.